Autolus Therapeutics plc (AUTL) Institutional Ownership

Ownership Summary

A total of 94 institutions have reported a stake in Autolus Therapeutics plc (NASDAQ:AUTL) as of September 2025, according to recent 13F filings with the SEC.

• These investors collectively held 54.3% of the company's total shares outstanding in September 2025, down from 58.4% in June 2025.
• The company experienced a 15.31% quarterly change in institutional shares held, alongside a decrease of 4.08% in total owners annually.
• Of these 94 institutional investors, 47 increased their holdings in Autolus Therapeutics, while 25 of them reduced positions, and 22 investors maintained their exposure.
• The total number of shares held by institutions in Autolus Therapeutics increased to 144.40Mn as of September 2025, a net change of up by 19.17Mn shares quarter on quarter, and down 33.47Mn shares year over year.
• With 26.02Mn shares, MAK CAPITAL ONE LLC commands the largest institutional position in Autolus Therapeutics as of September 30, 2025, equating to 9.78% of the company.
• Among the most significant buyers of Autolus Therapeutics during September 2025 were MAK CAPITAL ONE LLC (9.06Mn), CITADEL ADVISORS LLC (5.86Mn), SCHRODER INVESTMENT MANAGEMENT GROUP (4.82Mn), ARMISTICE CAPITAL, LLC (3.60Mn), AXA Investment Managers S.A. (3.36Mn).
• Leading sellers of Autolus Therapeutics stock in September 2025 included Deep Track Capital, LP (14.28Mn), MILLENNIUM MANAGEMENT LLC (1.59Mn), Affinity Asset Advisors, LLC (1.29Mn), Perpetual Ltd (348.01K), DAFNA Capital Management LLC (246.30K).
• The top 10 institutional holders of Autolus Therapeutics for the quarter ending September 2025 included MAK CAPITAL ONE LLC (26.02Mn), Blackstone Inc. (20.49Mn), Syncona Portfolio Ltd (16.64Mn), ARMISTICE CAPITAL, LLC (15.60Mn), TFG Asset Management GP Ltd (9.50Mn), SCHRODER INVESTMENT MANAGEMENT GROUP (8.43Mn), CITADEL ADVISORS LLC (6.04Mn), RENAISSANCE TECHNOLOGIES LLC (4.88Mn), Frazier Life Sciences Management, L.P. (4.62Mn), BlackRock, Inc. (3.47Mn).